FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308381569> ?p ?o ?g. }

• W4308381569 abstract "<h3>Background</h3> CD137 (TNFRSF9, 4-1BB) is a member of the tumor necrosis factor receptor superfamily that functions as a costimulatory molecule of immunocytes. Agonistic antibodies against CD137 have shown promising therapeutic activity in mouse tumor models. However, molecules in clinical development have shown limitations due to either dose-dependent severe liver toxicity or modest antitumor activity. We developed ZG033, a fully human IgG4 agonist of CD137 that engages with an exclusive epitope, to achieve a better efficacy and safety profile for immunotherapy. <h3>Methods</h3> The biophysical properties and activities were determined using multiple<i> in vitro</i> assays, incuding enzyme-linked immunosorbent assay (ELISA), surface plasmon resonance (SPR), cell-based and reporter gene assays. <i>In vivo</i> antitumor activities were assessed in human 4-1BB transgenic mice transplanted with human colon cancer cell line MC38. The pharmacokinetic (PK) behavior and safety profiles of ZG033 were characterized in cynomolgus monkeys. <h3>Results</h3> ZG033 is a safe and potent antibody injection associated with a differentiated pharmacology and toxicology profile. The structure of the ZG033/CD137 complex was determined by X-ray crystallography. The Fab of ZG033 binds CD137 at an obvious competitive epitope with the CD137 ligand, which differs from the currently known agonist antibodies of CD137. The residues T61A and I64R play a vital role in the formation of the complex, which was demonstrated by affinity assays. The binding affinity to human 4-1BB of ZG033 determined by surface plasmon resonance (SPR) was moderate (KD=10 nM). ZG033 increased CD137-driven NFκB reporter gene activation and the production of IFN-γ by human T cells in an FcγR–dependent manner. In human 4-1BB transgenic mice, ZG033 showed robust single-agent antitumor activity and induced durable antigen-specific immunological memory that prevented the tumor formation in the rechallenged mice. To determine the safety of ZG033, we incubated ZG033 with peripheral blood mononuclear cells (PBMCs) from healthy donors (n=4) and proved that it does not induce nonspecific production of proinflammatory cytokines. The results in 5-week I.V. repeated-dose (3, 10 and 30 mg/kg) and single-dose toxicity studies (60 and 180 mg/kg) suggested that ZG033 was well tolerated in cynomolgus monkeys with no abnormal hepatic or renal function and hematological index. <h3>Conclusions</h3> These data demonstrate that ZG033 acts as an FcγR crosslinking-dependent CD137 agonist that displays a favorable safety profile and has potential in either mono- or combinational immunotherapies." @default.
• W4308381569 created "2022-11-11" @default.
• W4308381569 creator A5014851777 @default.
• W4308381569 creator A5027492768 @default.
• W4308381569 creator A5056127229 @default.
• W4308381569 creator A5066588409 @default.
• W4308381569 creator A5080990029 @default.
• W4308381569 date "2022-11-01" @default.
• W4308381569 modified "2023-09-25" @default.
• W4308381569 title "1056 ZG033, a novel CD137 agonist, induces superior anti-tumor activity without hepatotoxicity rely on Fc-mediated crosslinking" @default.
• W4308381569 doi "https://doi.org/10.1136/jitc-2022-sitc2022.1056" @default.
• W4308381569 hasPublicationYear "2022" @default.
• W4308381569 type Work @default.
• W4308381569 citedByCount "0" @default.
• W4308381569 crossrefType "proceedings-article" @default.
• W4308381569 hasAuthorship W4308381569A5014851777 @default.
• W4308381569 hasAuthorship W4308381569A5027492768 @default.
• W4308381569 hasAuthorship W4308381569A5056127229 @default.
• W4308381569 hasAuthorship W4308381569A5066588409 @default.
• W4308381569 hasAuthorship W4308381569A5080990029 @default.
• W4308381569 hasBestOaLocation W43083815691 @default.
• W4308381569 hasConcept C106847996 @default.
• W4308381569 hasConcept C116569031 @default.
• W4308381569 hasConcept C12554922 @default.
• W4308381569 hasConcept C150903083 @default.
• W4308381569 hasConcept C153911025 @default.
• W4308381569 hasConcept C154317977 @default.
• W4308381569 hasConcept C155672457 @default.
• W4308381569 hasConcept C159654299 @default.
• W4308381569 hasConcept C170493617 @default.
• W4308381569 hasConcept C171250308 @default.
• W4308381569 hasConcept C185592680 @default.
• W4308381569 hasConcept C192562407 @default.
• W4308381569 hasConcept C195616568 @default.
• W4308381569 hasConcept C202751555 @default.
• W4308381569 hasConcept C203014093 @default.
• W4308381569 hasConcept C207001950 @default.
• W4308381569 hasConcept C2778938600 @default.
• W4308381569 hasConcept C2780249625 @default.
• W4308381569 hasConcept C502942594 @default.
• W4308381569 hasConcept C55493867 @default.
• W4308381569 hasConcept C86803240 @default.
• W4308381569 hasConcept C98274493 @default.
• W4308381569 hasConceptScore W4308381569C106847996 @default.
• W4308381569 hasConceptScore W4308381569C116569031 @default.
• W4308381569 hasConceptScore W4308381569C12554922 @default.
• W4308381569 hasConceptScore W4308381569C150903083 @default.
• W4308381569 hasConceptScore W4308381569C153911025 @default.
• W4308381569 hasConceptScore W4308381569C154317977 @default.
• W4308381569 hasConceptScore W4308381569C155672457 @default.
• W4308381569 hasConceptScore W4308381569C159654299 @default.
• W4308381569 hasConceptScore W4308381569C170493617 @default.
• W4308381569 hasConceptScore W4308381569C171250308 @default.
• W4308381569 hasConceptScore W4308381569C185592680 @default.
• W4308381569 hasConceptScore W4308381569C192562407 @default.
• W4308381569 hasConceptScore W4308381569C195616568 @default.
• W4308381569 hasConceptScore W4308381569C202751555 @default.
• W4308381569 hasConceptScore W4308381569C203014093 @default.
• W4308381569 hasConceptScore W4308381569C207001950 @default.
• W4308381569 hasConceptScore W4308381569C2778938600 @default.
• W4308381569 hasConceptScore W4308381569C2780249625 @default.
• W4308381569 hasConceptScore W4308381569C502942594 @default.
• W4308381569 hasConceptScore W4308381569C55493867 @default.
• W4308381569 hasConceptScore W4308381569C86803240 @default.
• W4308381569 hasConceptScore W4308381569C98274493 @default.
• W4308381569 hasLocation W43083815691 @default.
• W4308381569 hasOpenAccess W4308381569 @default.
• W4308381569 hasPrimaryLocation W43083815691 @default.
• W4308381569 hasRelatedWork W1796716201 @default.
• W4308381569 hasRelatedWork W1856085589 @default.
• W4308381569 hasRelatedWork W1904422975 @default.
• W4308381569 hasRelatedWork W2068999859 @default.
• W4308381569 hasRelatedWork W2416964709 @default.
• W4308381569 hasRelatedWork W2433311123 @default.
• W4308381569 hasRelatedWork W2622510373 @default.
• W4308381569 hasRelatedWork W2800648910 @default.
• W4308381569 hasRelatedWork W2953758866 @default.
• W4308381569 hasRelatedWork W3179304740 @default.
• W4308381569 isParatext "false" @default.
• W4308381569 isRetracted "false" @default.
• W4308381569 workType "article" @default.